PL2972368T3 - Biomarkery limfocytów do określania odpowiedzi klinicznej na terapię komórkową - Google Patents
Biomarkery limfocytów do określania odpowiedzi klinicznej na terapię komórkowąInfo
- Publication number
- PL2972368T3 PL2972368T3 PL14712628T PL14712628T PL2972368T3 PL 2972368 T3 PL2972368 T3 PL 2972368T3 PL 14712628 T PL14712628 T PL 14712628T PL 14712628 T PL14712628 T PL 14712628T PL 2972368 T3 PL2972368 T3 PL 2972368T3
- Authority
- PL
- Poland
- Prior art keywords
- determining
- cell therapy
- clinical response
- biomarkers
- lymphocyte
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title 1
- 238000002659 cell therapy Methods 0.000 title 1
- 210000004698 lymphocyte Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382091 | 2013-03-15 | ||
| PCT/EP2014/055282 WO2014140362A2 (en) | 2013-03-15 | 2014-03-17 | Lymphocyte biomarkers for determining the clinical response to cell therapy |
| EP14712628.8A EP2972368B1 (en) | 2013-03-15 | 2014-03-17 | Lymphocyte biomarkers for determining the clinical response to cell therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2972368T3 true PL2972368T3 (pl) | 2020-03-31 |
Family
ID=48044710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14712628T PL2972368T3 (pl) | 2013-03-15 | 2014-03-17 | Biomarkery limfocytów do określania odpowiedzi klinicznej na terapię komórkową |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10660920B2 (enExample) |
| EP (2) | EP2972368B1 (enExample) |
| JP (2) | JP6567430B2 (enExample) |
| AU (2) | AU2014230014B2 (enExample) |
| CA (2) | CA2906299C (enExample) |
| DK (1) | DK2972368T3 (enExample) |
| ES (1) | ES2748825T3 (enExample) |
| HU (1) | HUE046531T2 (enExample) |
| IL (1) | IL241586B (enExample) |
| PL (1) | PL2972368T3 (enExample) |
| PT (1) | PT2972368T (enExample) |
| SG (1) | SG11201507521UA (enExample) |
| WO (1) | WO2014140362A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060045872A1 (en) | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
| JP5925408B2 (ja) | 2005-09-23 | 2016-05-25 | タイジェニックス、ソシエダッド、アノニマ、ウニペルソナルＴｉｇｅｎｉｘ Ｓ．Ａ．Ｕ． | 免疫調節活性を有する細胞集団、単離方法および使用 |
| AU2014230014B2 (en) | 2013-03-15 | 2019-11-14 | Tigenix, S.A.U. | Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(MSC) |
| WO2016170187A2 (en) * | 2015-04-24 | 2016-10-27 | Tigenix, S.A.U | Biomarkers for determining the clinical response to cell therapy |
| GB201604304D0 (en) * | 2016-03-14 | 2016-04-27 | Tigenix S A U | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
| CA3043594C (en) * | 2016-11-11 | 2025-10-07 | Longeveron Llc | Methods of using human mesenchymal stem cells to effect cellular and humoral immunity |
| CN113544261B (zh) * | 2019-02-27 | 2024-10-01 | 武田药品工业株式会社 | 用于同种异体疗法的改良的干细胞群 |
| WO2021207192A1 (en) * | 2020-04-08 | 2021-10-14 | Figene, Llc | Methods and compositions for allergy and asthma treatment using fibroblasts |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60043511D1 (de) * | 1999-10-20 | 2010-01-21 | Chugai Pharmaceutical Co Ltd | Verwendung von g-csf zur hemmung der gvhd |
| EP2298861B1 (en) * | 2004-03-22 | 2017-09-13 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
| EP1871419A4 (en) * | 2005-04-22 | 2009-01-14 | Univ Maryland | METHODS OF TREATING REJECTION OF GRAFT AGAINST HOST |
| US8785190B2 (en) * | 2011-04-06 | 2014-07-22 | Sanbio, Inc. | Methods and compositions for modulating peripheral immune function |
| AU2014230014B2 (en) | 2013-03-15 | 2019-11-14 | Tigenix, S.A.U. | Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(MSC) |
-
2014
- 2014-03-17 AU AU2014230014A patent/AU2014230014B2/en active Active
- 2014-03-17 SG SG11201507521UA patent/SG11201507521UA/en unknown
- 2014-03-17 WO PCT/EP2014/055282 patent/WO2014140362A2/en not_active Ceased
- 2014-03-17 CA CA2906299A patent/CA2906299C/en active Active
- 2014-03-17 US US14/776,233 patent/US10660920B2/en active Active
- 2014-03-17 EP EP14712628.8A patent/EP2972368B1/en active Active
- 2014-03-17 PT PT147126288T patent/PT2972368T/pt unknown
- 2014-03-17 DK DK14712628.8T patent/DK2972368T3/da active
- 2014-03-17 PL PL14712628T patent/PL2972368T3/pl unknown
- 2014-03-17 HU HUE14712628A patent/HUE046531T2/hu unknown
- 2014-03-17 JP JP2015562256A patent/JP6567430B2/ja active Active
- 2014-03-17 ES ES14712628T patent/ES2748825T3/es active Active
- 2014-03-17 CA CA3188652A patent/CA3188652A1/en active Pending
- 2014-03-17 EP EP19187915.4A patent/EP3581932A1/en active Pending
-
2015
- 2015-09-16 IL IL241586A patent/IL241586B/en active IP Right Grant
-
2019
- 2019-07-31 JP JP2019140842A patent/JP6883070B2/ja active Active
-
2020
- 2020-02-05 AU AU2020200807A patent/AU2020200807B2/en active Active
- 2020-04-21 US US16/854,294 patent/US11478511B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014230014A1 (en) | 2015-10-29 |
| EP2972368B1 (en) | 2019-07-24 |
| ES2748825T3 (es) | 2020-03-18 |
| AU2014230014B2 (en) | 2019-11-14 |
| IL241586B (en) | 2019-02-28 |
| EP3581932A1 (en) | 2019-12-18 |
| CA2906299C (en) | 2023-04-04 |
| DK2972368T3 (da) | 2019-10-07 |
| WO2014140362A3 (en) | 2015-04-16 |
| US11478511B2 (en) | 2022-10-25 |
| HK1219775A1 (en) | 2017-04-13 |
| SG11201507521UA (en) | 2015-10-29 |
| JP2019215359A (ja) | 2019-12-19 |
| JP6567430B2 (ja) | 2019-08-28 |
| CA2906299A1 (en) | 2014-09-18 |
| US20160067285A1 (en) | 2016-03-10 |
| JP2016516985A (ja) | 2016-06-09 |
| AU2020200807B2 (en) | 2021-10-28 |
| AU2020200807A1 (en) | 2020-02-20 |
| JP6883070B2 (ja) | 2021-06-09 |
| PT2972368T (pt) | 2019-10-18 |
| WO2014140362A2 (en) | 2014-09-18 |
| US20200261511A1 (en) | 2020-08-20 |
| EP2972368A2 (en) | 2016-01-20 |
| HUE046531T2 (hu) | 2020-03-30 |
| US10660920B2 (en) | 2020-05-26 |
| CA3188652A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2516513B (en) | Multiple Viewshed analysis | |
| EP3480321B8 (en) | Massively parallel single cell analysis | |
| SI2946424T1 (sl) | Akumulatorska enota za plovilo | |
| IL245573A0 (en) | cell | |
| SG11201506644XA (en) | Cell-based tissue analysis | |
| HUE058243T2 (hu) | Afukozilált, FGFR2IIIB elleni antitestek | |
| GB2527441B (en) | Analysis system | |
| PL2972368T3 (pl) | Biomarkery limfocytów do określania odpowiedzi klinicznej na terapię komórkową | |
| DE112013002360T8 (de) | Reagenzinjektor | |
| PL2784454T3 (pl) | Diagnostyka ogniwa obciążnikowego | |
| GB201300650D0 (en) | Analysis system | |
| EP3058347A4 (en) | Photometric measurement cell | |
| EP3052943A4 (en) | Biomarkers for cell therapy | |
| HUP1200239A2 (en) | Quantitative biomarkers of the erythrocyte membrane | |
| GB201309561D0 (en) | Liquid conductivity measurement cell | |
| GB201310031D0 (en) | Cell | |
| GB2510124B (en) | Charging indicator | |
| IL255243A0 (en) | Biomarkers to determine clinical response to cellular therapy | |
| EP3036542A4 (en) | Blood analysis | |
| GB201317355D0 (en) | Mutation Analysis | |
| GB2519937B (en) | Electrochemical sensor | |
| GB201316131D0 (en) | Biomarkers for disease stratification | |
| GB2510126B (en) | Charging indicator | |
| GB201303158D0 (en) | Ritalinic Acid Immunoassay | |
| GB201315532D0 (en) | Methods for detecting proteins |